| Literature DB >> 30583518 |
Bridget A Baxter1, Renee C Oppel2, Elizabeth P Ryan3.
Abstract
Colorectal cancer (CRC) is the third leading cause of cancer-related death in the United States and emerging evidence supports that increased consumption of legumes, such as navy beans, can reduce risk. Navy bean consumption was previously shown to modulate host and microbiome metabolism, and this investigation was performed to assess the impact on the human stool metabolome, which includes the presence of navy bean metabolites. This 4-week, randomized-controlled trial with overweight and obese CRC survivors involved consumption of 1 meal and 1 snack daily. The intervention contained 35 g of cooked navy bean or macronutrient matched meals and snacks with 0 g of navy beans for the control group (n = 18). There were 30 statistically significant metabolite differences in the stool of participants that consumed navy bean at day 28 compared to the participants' baseline (p ≤ 0.05) and 26 significantly different metabolites when compared to the control group. Of the 560 total metabolites identified from the cooked navy beans, there were 237 possible navy bean-derived metabolites that were identified in the stool of participants consuming navy beans, such as N-methylpipecolate, 2-aminoadipate, piperidine, and vanillate. The microbial metabolism of amino acids and fatty acids were also identified in stool after 4 weeks of navy bean intake including cadaverine, hydantoin-5 propionic acid, 4-hydroxyphenylacetate, and caprylate. The stool relative abundance of ophthalmate increased 5.25-fold for navy bean consumers that can indicate glutathione regulation, and involving cancer control mechanisms such as detoxification of xenobiotics, antioxidant defense, proliferation, and apoptosis. Metabolic pathways involving lysine, and phytochemicals were also modulated by navy bean intake in CRC survivors. These metabolites and metabolic pathways represent an acute response to increased navy bean intake, which merit further investigation for improving colonic health after long-term consumption.Entities:
Keywords: colorectal cancer; dietary intervention; metabolomics; microbial metabolism; navy beans; stool
Mesh:
Substances:
Year: 2018 PMID: 30583518 PMCID: PMC6356708 DOI: 10.3390/nu11010028
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Baseline characteristics of study population.
| Control ( | Navy Bean ( | |
|---|---|---|
| Age (years) | 65.50 ± 3.07 | 60.9 ± 11.0 |
| Sex | 4 (40%) | 2 (22%) |
| Males (%) Females (%) | 6 (60%) | 7 (78%) |
| BMI (kg/m2) | 27.26 ± 3.29 | 25.9 ± 5.0 |
| Fiber Intake | 25.07 ± 11.2 | 19.94 ± 10.0 |
Values are presented as mean ± SD.
Figure 1Median scaled relative abundances of selected navy bean metabolites classified as (A) lipids, and (B) amino acids. A complete list of the identified navy bean metabolites with the relative abundances can be found in Supplemental Table S1.
Figure 2Stool metabolic pathways impacted by navy bean consumption as measured by pathway enrichment score (PES) for day 28 when compared to day 0 (baseline). (A) All stool metabolic pathways with a PES >2.0 are shown. Selected pathways with metabolites were shown for (B) tetrahydrobiopterin (1 metabolite) PES 28.4 (C) fatty acid, amino (2 metabolites) PES 14.2, and (D) inositol metabolism (4 metabolites), PES 7.1. Metabolites with black node were not significantly changed by beans. Red nodes indicate significantly increased metabolite abundance and blue node represents significantly decreased metabolite after consuming navy beans for 28 days compared to baseline (day 0). The size of the circle reflects the relative abundance scaled to all stool metabolites. The * indicates presence in the navy bean metabolome.
Figure 3Stool metabolic pathways impacted by navy beans consumption as measured by pathway enrichment score (PES) and compared to control at day 28. (A) All metabolic pathways with a PES > 2.0, (B) glutathione metabolism (4 identified navy bean metabolites) PES 12.5, and (C) histidine metabolism (8 identified navy bean metabolites) PES 3.9. Red nodes indicate significant increase, blue node is significant decrease, and light pink shows trending increase in abundance between navy beans and control group at 28 days. The size of the circle reflects the relative abundance when scaled to all stool metabolites. The * indicates presence in the navy bean metabolome listed in Supplementary Table S1.
Stool metabolites that change over time from participants consuming control or navy bean intervention meals and snacks.
| Metabolic Pathway | Biochemical Name | Control | Navy Beans | ||
|---|---|---|---|---|---|
| Fold Change | Fold Change | ||||
|
| |||||
| Alanine and Aspartate |
| 0.0498 | 0.88 | 0.8519 | |
|
| 0.0062 | 0.74 | 0.8716 | ||
| Glutamate | glutamate | 1.14 | 0.2647 |
| 0.0372 |
| Lysine | 2-aminoadipate |
| 0.0331 | 1.01 | 0.5629 |
| cadaverine | 1.20 | 0.961 |
| 0.0009 | |
| Phenylalanine and Tyrosine | 4-hydroxyphenylacetate | 1.03 | 0.7962 |
| 0.0181 |
| 3-hydroxyphenylacetate |
| 0.0020 | 0.77 | 0.7575 | |
| phenylacetylglutamine | 1.68 | 0.8156 |
| 0.0494 | |
| 2-(4-hydroxyphenyl)propionate | 1.22 | 0.2846 |
| 0.0110 | |
| Tryptophan | tryptamine |
| 0.0032 | 0.29 | 0.1752 |
| Methionine, Cysteine, S-adenosylmethione (SAM) and Taurine | 1.17 | 0.6650 |
| 0.0428 | |
| homocysteine |
| 0.003 | 1.11 | 0.5865 | |
| Creatine | creatine | 0.78 | 0.9114 |
| 0.0074 |
| guanidinoacetate | 3.21 | 0.4745 |
| 0.0497 | |
| Glutathione | ophthalmate | 1.13 | 0.8969 |
| 0.0116 |
|
| |||||
| Pentose | ribose |
| 0.0261 | 0.92 | 0.7411 |
| ribonate |
| 0.0159 | 0.91 | 0.9095 | |
| xylonate |
| 0.0029 | 1.57 | 0.3878 | |
| 2-deoxyribose | 1.42 | 0.1133 |
| 0.0269 | |
| Aminosugar | diacetylchitobiose | 1.89 | 0.6057 |
| 0.0066 |
| Advanced Glycation |
| 0.0076 | 0.95 | 0.6244 | |
|
| |||||
| Medium Chain Fatty Acid | caprylate (8:0) | 3.94 | 0.1863 |
| 0.0441 |
| laurate (12:0) |
| 0.0175 | 0.14 | 0.4344 | |
| Long Chain Fatty Acid | myristate (14:0) |
| 0.0186 | 0.37 | 0.4247 |
| cis-vaccenate (18:1 |
| 0.0335 | 0.94 | 0.7617 | |
| Polyunsaturated Fatty Acid ( | docosahexaenoate (DHA; 22:6 |
| 0.0099 | 1.13 | 0.6900 |
| docosatrienoate (22:3 |
| 0.0094 | 1.36 | 0.8702 | |
| linoleate (18:2 |
| 0.0499 | 0.84 | 0.6734 | |
| arachidonate (20:4 |
| 0.0128 | 1.05 | 0.9502 | |
| docosadienoate (22:2 |
| 0.0414 | 1.79 | 0.8219 | |
| Fatty Acid, Amino | 2-aminooctanoate | 0.99 | 0.154 |
| 0.0285 |
| Fatty Acid, Monohydroxy | 3-hydroxysebacate |
| 0.0242 | 0.54 | 0.7037 |
| Inositol | scyllo-inositol | 0.74 | 0.2135 |
| 0.0473 |
| Glycerolipid | glycerol 3-phosphate (G3P) | 1.00 | 1.0000 |
| 0.0454 |
| Monoacylglycerol | 1-myristoylglycerol (1-monomyristin) |
| 0.0384 |
| 0.0132 |
| Sphingolipid |
| 0.0159 | 0.50 | 0.4079 | |
| Steroid | 5alpha-androstan-3alpha,17beta-diol disulfate |
| 0.0453 | 0.63 | 0.5735 |
| Secondary Bile Acid | 7,12-diketolithocholate |
| 0.0251 | 23.33 | 0.5602 |
| 6-oxolithocholate | 1.02 | 0.9860 |
| 0.0210 | |
| glycocholenate sulfate * | 1.10 | 0.3844 |
| 0.0118 | |
|
| |||||
| Purine, (Hypo)Xanthine/Inosine containing | hypoxanthine |
| 0.0258 | 1.46 | 0.8596 |
| Purine, Adenine containing | adenosine-2′,3′-cyclic monophosphate | 1.00 | 1.0000 |
| 0.0413 |
| Pyrimidine, Thymine containing | 5,6-dihydrothymine | 1.15 | 0.4695 |
| 0.0209 |
|
| |||||
| Ascorbate and Aldarate | ascorbate (Vitamin C) | 0.95 | 0.8606 |
| 0.0130 |
| Tocopherol | gamma-CEHC | 0.62 | 0.6196 |
| 0.0248 |
| Tetrahydrobiopterin | biopterin | 1.06 | 0.8275 |
| 0.0444 |
| Benzoate | 3-hydroxybenzoate |
| 0.0112 | 0.51 | 0.3146 |
| catechol sulfate | 0.48 | 0.3614 |
| 0.0376 | |
| 3-(2-hydroxyphenyl)propionate |
| 0.0005 |
| 0.0059 | |
| Xanthine | 1-methylurate |
| 0.0151 | 0.46 | 0.5649 |
| 7-methylurate |
| 0.0275 | 0.27 | 0.1830 | |
| 1,3-dimethylurate | 1.07 | 0.6615 |
| 0.0112 | |
| 1-methylxanthine |
| 0.0466 | 1.12 | 0.9862 | |
| 7-methylxanthine |
| 0.0202 | 0.31 | 0.1809 | |
| Other Phytochemicals | piperidine | 0.48 | 0.3284 |
| 0.0176 |
| 2-piperidinone |
| 0.0190 | 1.16 | 0.8974 | |
| (15:0)-anacardic acid | 1.65 | 0.8377 |
| 0.0448 | |
| apigenin |
| 0.0001 | 0.46 | 0.5761 | |
| luteolin |
| 0.0299 | 0.35 | 0.7539 | |
| abscisate |
| 0.0138 | 0.62 | 0.8696 | |
| enterolactone |
| 0.0278 |
| 0.0017 | |
| indolin-2-one |
| 0.0013 | 1.13 | 0.6222 | |
| sitostanol |
| 0.0060 |
| 0.0767 | |
| Diphenhydramine (drug) |
| 0.0429 | 1.00 | 1.0000 | |
| loperamide |
| 0.0324 | 1.00 | 1.0000 | |
| salicylate |
| 0.0179 | 1.08 | 0.3910 | |
| 0.83 | 0.3601 |
| 0.0038 | ||
Median scaled relative abundances were assessed for changes at day 28 when compared to baseline (day 0). Bolded fold change values were statistically significant (p value > 0.05). * Indicates compounds that did not have a standard, and identification was matched to a database.
Stool metabolites with statistically significant fold differences in abundance were identified between groups at day 28 following completion of the navy beans or control dietary intervention.
| Metabolic Pathway | Metabolite | HMDB | Navy Bean day 28 | Control day 28 | Fold Difference (NB/Control) | |
|---|---|---|---|---|---|---|
|
| ||||||
| Histidine | formiminoglutamate | 0.564 | 5.328 | 0.11 | 0.019 | |
| hydantoin-5-propionic acid | HMDB01212 | 0.829 | 0.249 | 3.71 | 0.016 | |
| Lysine | 2-aminoadipate | HMDB00510 | 1.741 | 0.695 | 2.69 | 0.000 |
| 1.553 | 0.512 | 3.17 | 0.032 | |||
| Leucine, Isoleucine and Valine | 4-methyl-2-oxopentanoate | HMDB00695 | 0.9896 | 2.5642 | 0.41 | 0.024 |
| 0.722 | 0.189 | 0.15 | 0.039 | |||
| 3-methyl-2-oxovalerate | HMDB03736 | 0.856 | 3.084 | 0.37 | 0.034 | |
| 3-methyl-2-oxobutyrate | HMDB00019 | 0.937 | 2.831 | 0.41 | 0.048 | |
| Glutathione | 5-oxoproline | HMDB00267 | 1.202 | 3.316 | 0.23 | 0.031 |
| ophthalmate | HMDB05765 | 1.480 | 0.282 | 3.49 | 0.031 | |
|
| ||||||
| Gamma-glutamyl Amino Acid | gamma-glutamylglutamine | HMDB11738 | 2.798 | 1.211 | 2.60 | 0.01 |
|
| ||||||
| TCA Cycle | malate | HMDB00156 | 0.690 | 1.464 | 0.39 | 0.029 |
|
| ||||||
| Medium Chain Fatty Acid | caprylate (8:0) | HMDB00482 | 0.682 | 4.610 | 0.1 | 0.020 |
| undecanoate (11:0) | HMDB00947 | 0.853 | 1.627 | 0.50 | 0.015 | |
| Polyunsaturated Fatty Acid ( | eicosapentaenoate (EPA; 20:5 | HMDB01999 | 4.014 | 25.09 | 0.05 | 0.031 |
| Fatty Acid (Acyl Glycine) | valerylglycine | HMDB00927 | 0.775 | 6.876 | 0.13 | 0.048 |
| Monoacylglycerol | 1-myristoylglycerol (1-monomyristin) | HMDB11561 | 0.875 | 2.246 | 0.31 | 0.039 |
| Secondary Bile Acid | glycolithocholate sulfate * | HMDB02639 | 0.802 | 1.487 | 0.39 | 0.035 |
| glycocholenate sulfate * | 0.171 | 1.750 | 0.10 | 0.026 | ||
|
| ||||||
| Purine | allantoin | HMDB00462 | 0.173 | 6.796 | 0.11 | 0.049 |
| Pyrimidine | 4-ureidobutyrate | 0.642 | 1.921 | 0.31 | 0.038 | |
| 5,6-dihydrothymine | HMDB1 | 0.626 | 0.416 | 1.56 | 0.047 | |
|
| ||||||
| Other Phytochemicals | vanillin | HMDB12308 | 1.228 | 1.515 | 0.51 | 0.036 |
| nobiletin | HMDB29540 | 0.528 | 0.371 | 1.48 | 0.048 | |
| salicylate | HMDB01895 | 2.142 | 3.094 | 0.77 | 0.043 |
HMDB, Human Metabolome Database; Values presented are fold-difference of the mean relative abundance between navy bean or control group compared to control at day 28. *Indicated compounds that did not have a standard, and identification was match to a database.
Figure 4Overlap between navy bean (food) metabolome and stool metabolome of navy bean consumers. (A) The stool metabolome contained 782 components and the overlap of metabolites from the cooked navy bean food (367 metabolites). Pathways of (B) lysine metabolism (16 metabolites) and (C) food and plant components (96 metabolites). Stool metabolites with black were not significant in the navy bean group over baseline. Red nodes indicate significant increase after consuming navy beans when compared to the baseline. The size of the circle relates to the relative abundance when scaled to all stool metabolites. The * indicates presence in the navy beans.